Well conducted research has shown that Hepatitis C virus infection can also promote immune attacks on the thyroid. The research has shown that both thyroid imbalance and thyroid anti-bodies are much more common in patients with Hepatitis C virus infection than in normal people. In fact, nearly 10% of patients with Hepatitis C have a thyroid disorder and positive thyroid anti-bodies.
The reason is that the Hepatitis C virus shares some molecular similarities with the thyroid and this may make the immune system mistakenly attack the thyroid gland in response to the presence of foreign molecules coming from the virus. The virus could also be infecting the thyroid cells and that could trigger the attack of the immune system on the thyroid gland. Alfa-interferon is a medication widely used to treat infections and cancer. This medication is also used to treat chronic Hepatitis C. It also happens that the medication Interferon can also trigger an auto-immune thyroid disease. So patients with Hepatitis C virus who are already pre-disposed to having an auto immune thyroid disease and are taking Alpha-Interferon are at higher risk of having an auto-immune thyroid condition.
It has been estimated that thyroid disorders may occur in as many as 20-40% and a significant thyroiditis may occur in 5-10% of patients treated with Alpha-Interferon. Interferon can cause both Hashimoto’s Thyroiditis and Graves Disease. If a person has positive anti-thyroid antibody prior to being treated with interferon, the risk of having a significant thyroiditis becomes quite high.
Interferon treatment can even trigger an auto-immune thyroiditis in people without thyroid anti-bodies. So if one has a genetic vulnerability to auto-immune thyroid disease, the use of interferon therapy makes the likelihood of having an auto-immune thyroid condition become more significant. Interferon can also cause a thyroiditis not mediated by the immune system but instead by a destruction of thyroid cells. This medication can directly destroy thyroid cells and makes thyroid hormone pour in our system. This ends up causing hyperthyroidism. Often the hyperthyroidism is followed by hypothyroidism as in Silent Thyroiditis. This is interpreted as a direct toxic effect of the medication.
Thyroid Disease: Dr. Val Jones
Adstract 2010
Thyroid Disorders in Hepatitis C Patients Treated or Not With [alpha]-Interferon and Ribavirin
Thyroid Disorders in Hepatitis C Patients Treated or Not With [alpha]-Interferon and Ribavirin Santos, Sandra Regina Xavier MD*; Ferreira, Marcelo Simão PhD†; Borges, Aércio Sebastião MD†; de Melo Costa Pinto, Rogério PhD‡; Pereira Mendonça Fernandes, Maria Luiza MD*; Jorge, Paulo Tannús PhD* Abstract α-interferon and ribavirin are the drugs of choice for treating Hepatitis C, but may trigger thyroid disorders as a major complication. Several studies have shown a variation in the prevalence (1%–35%) of this association influenced by geographical distribution, genetics, and iodine intake of the population.
The objective of this study was to analyze thyroid disorders in patients with hepatitis C in treatment or not with α-interferon and ribavirin.
We evaluated the frequency and pattern of thyroid disorders in 25 patients with hepatitis C in treatment with α-interferon and ribavirin (Genotype 1), 62 patients with hepatitis C without treatment (Genotype 2) and 82 patients without hepatitis C (control group) measuring thyroid-stimulant hormone, antiperoxidase antibodies (anti-TPO), and anrtithyroglobulin (anti-TG).
Hypothyroidism was more frequent in hepatitis C patients under treatment (36%), while the frequency of thyroid antibodies was not different in the 3 studied groups, respectively (12% in Genotype 1; 8.06% in Genotype 2, and 17.07% in control group).
It was not possible to demonstrate the higher prevalence of autoimmune thyroid disease in hepatitis C carriers under treatment with α-interferon and ribavirin; even though hypothyroidism is more frequent in this group. Patients with hepatitis C treated with these medications should be screened for thyroid dysfunction.
In 2009 data published at Medscape by Crystal Phend :
Excerpt:"Screening and proper management of thyroid diseases in patients with diabetes or hepatitis C virus infection may help prevent hepatocellular cancer," they said. These case-control study findings shouldn't be surprising, the researchers wrote in the May issue of Hepatology. Hypothyroidism has been linked to chronic liver diseases and implicated in the pathogenesis of nonalcoholic steatohepatitis (NASH), which is considered a predisposing condition for liver cancer. This may result from the essential role of thyroid hormones in lipid mobilization and degradation and fatty acid oxidation, Dr. Hassan's group said. When they're out of balance, "all of these conditions may enhance the susceptibility to chronic inflammation, DNA damage, and hepatocellular carcinoma development."
.
Personal Experiences With Thyroid Disease in Men and Women
"According to the American Association of Clinical Endocrinologists (AACE), millions of women with unresolved menopausal-like symptoms, even those taking estrogen, may be suffering from undiagnosed thyroid disease. While symptoms such as fatigue, depression, mood swings, and sleep disturbances are frequently associated with menopause, they may also be signs of hypothyroidism. A survey done by the AACE showed that only 1 in 4 women who have discussed menopause and its symptoms with a physician were also tested for thyroid disease. The thyroid plays a role in regulating overall body metabolism and influences the heart, brain, kidney, and reproductive system, along with muscle strength and appetite". .
Thyroid Disease In Men
Symptoms of Thyroid Disease in Men "The thyroid hormone is one of many necessary hormones for men's health. Although the majority of information regarding thyroid health is focused on women, men also suffer from thyroid dysfunction and the associated symptoms".
Thyroid disorders cause sexual dysfunction in men is detected by the Scientists. Sexual dysfunction in men is caused by many reasons like heart diseases, emotional disorders, excess of steroid intake, and dysthamia. Researchers have claimed that one of common cause for the sexual dysfunction in men is the thyroid disorders
DDW 2012 Clinicians, researchers and scientists from around the world will gather for Digestive Disease Week® (DDW) 2012, the largest and most prestigious gastroenterology meeting, from May 19-22, 2012, at the San Diego Convention Center, CA. DDW, the annual meeting of the American Gastroenterological Association (AGA) Institute, is jointly sponsored by the American Association for the Study of Liver Diseases, the AGA, the American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract. Click here for updates
May 18-2012 U.S. health officials want all baby boomers to get tested for hepatitis C. The Centers for Disease Control and Prevention on Friday released draft recommendations calling for all baby boomers to get a one-time blood test for the liver disease. That's everyone born from 1945 to 1965. CDC - Draft Recommendations
Find Hepatitis Testing Year Round Near You Locate organizations offering Hepatitis testing and additional services vaccines and treatment in the NPIN Organizations Database.
A special supplementary issue of Gastroenterology with full text viral hepatitis review articles and commentaries available through open access. Click here to view an index of articles.
A Few Topics Include; Maximizing Opportunities and Avoiding Mistakes in Triple Therapy for Hepatitis C Virus
Will Interferon-Free Regimens Prevail?
Books Free from Hepatitis C About the Author Lucinda K. Porter, RN is an active hepatitis C advocate who writes, teaches, and lectures on the topic. She is recognized as a leader in her field based upon her professional experience and her first hand knowledge of living with the disease.
Ms. Porter has been a research nurse at Stanford University Medical Center specializing in HCV and her articles and guides have appeared in numerous HCV newsletters and journals.
Today, in addition to being a highly sought-after speaker, she continues to work with various HCV groups on behalf of patients and their families
Alisporivir-Three cases of acute pancreatitis, one fatal, have led the FDA to put a clinical hold on a trial of an investigational oral drug for hepatitis C called alisporivir, according to the product's manufacturer.
Projects In Knowledge Offered at the site is a program series of HCV Video Case Vignettes.In the videos individual patient case studies are discussed, topics include side effects, drug-drug interactions, treatment duration, and outcome.
AASLD - Liver Learning If you haven't yet explored the "Liver Learning" section available @ the AASLD web site you're missing out on the November meeting webcasts, video podcasts, abstracts and more.
2012 March 2012-New Antiviral Agents for Hepatitis C This article describes the direct acting antivirals and host-targeted agents that have recently been approved or have been tested in HCV-infected patients and discusses their two current paths of clinical development: with or without interferon-α.
Protease inhibitors: Silver bullets for chronic hepatitis C infection? Recent trials evaluated the safety and efficacy of two protease inhibitors, boceprevir (Victrelis) and telaprevir (Incivek), added to standard care with pegylated interferon and ribavirin, in patients with chronic hepatitis C virus (HCV) infection. These drugs open the door for triple therapy and other new therapies involving combinations of other direct-acting antiviral agents to become the new standard of care for this population.
Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir A significant increase in the number of patients with CHC to be treated is expected for 2012, with triple therapy regimens that are more complex. These expected developments represent a significant challenge and will stretch current resources. The present Swiss Association for the Study of the Liver (SASL) expert opinion statement is not intended as guideline but shall provide some guidance on the management of CHC genotype 1 and the use of TPV and BOC
By joining networked blogs readers will be able to view all blog updates as they appear on the blog. *The majority of HCV news, research and updates are not posted on this blogs facebook page.
Clinical Trials-
To learn more about Hepatitis C virus clinical trials or to find out if a study is enrolling patients in your area, please click here.
Hepatitis C-New Protease Inhibitor (NS3/4A) Drug Resistance Test LabCorp has begun offering nationwide its hepatitis C GenoSure NS3/4A assay, which is designed to identify NS3 and NS4A mutations and NS3-associated resistance to a pair of recently approved HCV protease inhibitors.
Multimedia-Videos and Podcasts
Can't Find What You're Looking For? Click On A Topic Below
SUPPORT A new national toll-free helpline has been launched for people affected by hepatitis C: 877-HELP-4-HEP (877-435-7443).
This new consumer-run helpline is staffed by specially trained peer counselors Monday through Friday, 9am to 7pm EST to provide emotional support, health information, and referrals.
HELP-4-HEP is a partnership among several well-known and nationally recognized nonprofits with a combined 90+ years’ experience in hepatitis C education, support and patient advocacy.
Click here to order a FREE Home Access Hepatitis C Test Kit
How Soon Should I Get Tested After Exposure ?
After the exposure (especially if the blood exposure involved another person known to have the hepatitis C virus), it is recommended that testing for the hepatitis C antibody be performed at 4 to 6 months after the exposure OR that testing for the hepatitis C virus itself (a test often called an HCV PCR or hepatitis C viral load test) be performed 4 to 6 weeks after the potential exposure. These tests are done to determine whether or not hepatitis C infection has occurred as a result of the exposure.;
FAIR USE NOTICE:
If this site contains copyrighted material the use of which has not been specifically authorized by the copyright owner, it is being made available in an effort to advance the understanding of the ethics dealing with medical practice, medical care, new drug research, drug trials, science and scientific research, human rights, social justice and, in addition, the law and politics which cover these areas. It is believed that this use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed to visitors of this “HCV New Drugs Blog” without profit to the blog or to those who by visiting this blog have expressed interest in receiving the included information for research and educational purposes. The material in this site is provided for educational and informational purposes only, and is not intended to be a substitute for a health care provider's consultation. Please consult your own appropriate health care provider about the applicability of any opinions or recommendations with respect to your own symptoms or medical conditions. The information on this site does not constitute legal or technical advice
Keeping current on the potential arrival of new, improved Hepatitis C drugs is a regular research venture for many who are living with the Hepatitis C virus.
I was 43, a mother of three when I found out I had HCV. I went on to be treated successfully in 2000.(Intron A/Riba).
Only people who have experienced a chronic illness understand the fear and apprehension felt with each step up the ladder, climbing closer to either medical treatment or a possible cure. These millions of people (I was one of them) who are living with chronic hepatitis C or just newly diagnosed are often left out in the cold, alone, with many unanswered questions. Enter the sleepless nights, anxiety, waking each day wondering what to do next.
My blog is here to help you learn about HCV, the new drugs to treat this disease along with news and updates.
Wishing you all a safe journey.
Tina
0 comments: